MariMed Inc. (OTCMKTS:MRMD – Get Free Report) saw a large increase in short interest in October. As of October 30th, there was short interest totaling 18,486 shares, an increase of 1,748.6% from the October 15th total of 1,000 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 761,607 shares, the days-to-cover ratio is currently 0.0 days.
MariMed Stock Performance
MariMed stock remained flat at $0.07 during trading hours on Thursday. The company’s stock had a trading volume of 66,769 shares, compared to its average volume of 580,535. MariMed has a 52-week low of $0.04 and a 52-week high of $0.16. The company has a current ratio of 0.92, a quick ratio of 0.34 and a debt-to-equity ratio of 1.78. The firm has a 50 day moving average price of $0.07 and a 200-day moving average price of $0.07. The firm has a market capitalization of $30.02 million, a price-to-earnings ratio of -1.86 and a beta of 1.54.
MariMed (OTCMKTS:MRMD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 11th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The business had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.20 million. MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%.
MariMed Company Profile
MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Featured Articles
- Five stocks we like better than MariMed
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
- Tesla’s Plan to End Cybertruck Reveals Its Real Priorities
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
